Literature DB >> 22183128

Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.

Paolo Pozzilli1.   

Abstract

Research in 2011 regarding β-cell destruction, early immunointervention trials and development of late complications in type 1 diabetes mellitus have highlighted the heterogeneity of this disease. Patient phenotyping should be performed for the implementation of tailored therapies, especially taking into account the age at which the disease is diagnosed.

Entities:  

Mesh：

Year:  2011        PMID： 22183128     DOI： 10.1038/nrendo.2011.228

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study.

Authors:  Marcus Lind; Ioannis Bounias; Marita Olsson; Soffia Gudbjörnsdottir; Ann-Marie Svensson; Annika Rosengren
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

2.  Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.

Authors:  M C Thomas; J Söderlund; M Lehto; V-P Mäkinen; J L Moran; M E Cooper; C Forsblom; P-H Groop
Journal:  Diabetologia       Date:  2011-05-24       Impact factor: 10.122

3.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Authors:  Tihamer Orban; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Philip Raskin; Henry Rodriguez; William E Russell; Desmond Schatz; Diane Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

4.  Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Authors:  Nicole Sherry; William Hagopian; Johnny Ludvigsson; Sunil M Jain; Jack Wahlen; Robert J Ferry; Bruce Bode; Stephen Aronoff; Christopher Holland; David Carlin; Karen L King; Ronald L Wilder; Stanley Pillemer; Ezio Bonvini; Syd Johnson; Kathryn E Stein; Scott Koenig; Kevan C Herold; Anastasia G Daifotis
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

5.  Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress.

Authors:  Phuong Oanh T Tran; Sarah M Parker; Eric LeRoy; Christopher C Franklin; Terrance J Kavanagh; Tao Zhang; Huarong Zhou; Portia Vliet; Elizabeth Oseid; Jamie S Harmon; R Paul Robertson
Journal:  J Biol Chem       Date:  2004-10-12       Impact factor: 5.157

6.  Response of human islets to isolation stress and the effect of antioxidant treatment.

Authors:  Rita Bottino; A N Balamurugan; Hubert Tse; C Thirunavukkarasu; Xinhui Ge; Jennifer Profozich; Martha Milton; Audra Ziegenfuss; Massimo Trucco; Jon D Piganelli
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

7.  Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study.

Authors:  Jennifer K Sun; Hillary A Keenan; Jerry D Cavallerano; Bela F Asztalos; Ernst J Schaefer; David R Sell; Christopher M Strauch; Vincent M Monnier; Alessandro Doria; Lloyd Paul Aiello; George L King
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

8.  Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes.

Authors:  Terri C Thayer; Matthew Delano; Chao Liu; Jing Chen; Lindsey E Padgett; Hubert M Tse; Mani Annamali; Jon D Piganelli; Lyle L Moldawer; Clayton E Mathews
Journal:  Diabetes       Date:  2011-06-29       Impact factor: 9.461

9.  C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.

Authors:  Raffaella Buzzetti; Simona Cernea; Antonio Petrone; Marco Capizzi; Marialuisa Spoletini; Simona Zampetti; Chiara Guglielmi; Chiara Venditti; Paolo Pozzilli
Journal:  Diabetes       Date:  2011-09-06       Impact factor: 9.461

10.  Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans.

Authors:  David J Klinke
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240
  10 in total
  6 in total

Review 1.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 2.  Type 1 diabetes.

Authors:  Mark A Atkinson; George S Eisenbarth; Aaron W Michels
Journal:  Lancet       Date:  2013-07-26       Impact factor: 79.321

3.  Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.

Authors:  Ronnie Aronson; Peter A Gottlieb; Jens S Christiansen; Thomas W Donner; Emanuele Bosi; Bruce W Bode; Paolo Pozzilli
Journal:  Diabetes Care       Date:  2014-07-10       Impact factor: 19.112

4.  Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).

Authors:  Takuya Awata; Akira Shimada; Taro Maruyama; Yoichi Oikawa; Nobuyuki Yasukawa; Susumu Kurihara; Yumi Miyashita; Masako Hatano; Yuichi Ikegami; Masafumi Matsuda; Masataka Niwa; Youichiro Kazama; Shoichiro Tanaka; Tetsuro Kobayashi
Journal:  Diabetes Ther       Date:  2017-09-19       Impact factor: 2.945

5.  The effect of spermidine on autoimmunity and beta cell function in NOD mice.

Authors:  Ceren Karacay; Barbara Prietl; Clemens Harer; Barbara Ehall; Christoph W Haudum; Kaddour Bounab; Joakim Franz; Tobias Eisenberg; Frank Madeo; Dagmar Kolb; Kerstin Hingerl; Markus Hausl; Christoph Magnes; Selma I Mautner; Petra Kotzbeck; Thomas R Pieber
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

Review 6.  Advances in the cellular immunological pathogenesis of type 1 diabetes.

Authors:  Min Li; Lu-Jun Song; Xin-Yu Qin
Journal:  J Cell Mol Med       Date:  2014-03-14       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.